Current Clinical Trials

REVATE TRIAL

Yin-Kai Chao, Zhi-Gang Li, Yu-Wen Wen, Dae-Joon Kim, Seong-Yong Park, Yu-Ling Chang, Pieter C. van der Sluis, Jelle P. Ruurda and Richard van Hillegersberg

Background: Radical lymph node dissection (LND) along the left recurrent laryngeal nerve (RLN) is surgically demanding and can be associated with substantial postoperative morbidity. The question  of  whether  robot- assisted esophagectomy (RE) might be superior to video-assisted thoracoscopic esophagectomy (VATE) for performing  LND along  the  RLN in patients with esophageal squamous  cell carcinoma  (ESCC)  remains  open.
Methods/design: We will conduct a multicenter, open-label, randomized controlled trial (Robotic-assisted Esophagectomy vs Video-Assisted Thoracoscopic Esophagectomy (REVATE)) enrolling patients with ESCC scheduled to undergo LND along the RLN. Patients will be randomly assigned to either RE or VATE. The  primary outcome measure will be the rate of unsuccessful LND  along the left RLN, which will be defined as: failure to remove lymph nodes along the left RLN (i.e., no identifiable nodes on pathology reports); or occurrence of permanent (duration > 6 months) left RLN palsy following LND. Secondary outcomes will include the number of successfully removed RLN nodes, postoperative recovery, length of hospital stay, 30-day and 90-day mortality, quality of life, and oncological outcomes.
Discussion: The REVATE study provides an  opportunity to explore whether RE could facilitate LND along the   left RLN—a complex surgical procedure that, as of now and with the use of VATE, remains difficult to perform and associated with a significant burden of morbidity.

ClinicalTrials.gov, NCT03713749. Registered on 22 October 2018.
Full study protocol accessible via Trials.